Watson Pharma has launched Vestura (3mg drospirenone and 0.02 mgethinyl estradiol), a generic version of Bayer HealthCare's Yaz oral contraceptive product.
Watson Pharma, a subsidiary of Watson Pharmaceuticals, has begun shipment of the product.
Vestura is indicated for the prevention of pregnancy and for the treatment of moderate acne in women.
Yaz and its generic versions had total US sales of approximately $510m for the year ending 30 November 2011, according to IMS Health.
Watson Pharmaceuticals is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on urology and women’s health.